Home › Multiple Myeloma › Georgia › Atlanta
Pag-aaral pangklinika para sa Multiple Myeloma sa Atlanta, GA
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Atlanta. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Atlanta
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Nagre-recruitPhase 1/2
- Emory University Winship Cancer Center, Atlanta
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Nagre-recruitPhase 3
- Emory University - Winship Cancer Institute, Atlanta
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Nagre-recruitPhase 1
- Winship Cancer Institute Emory University, Atlanta
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Emory University, Atlanta
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Emory University Winship Cancer Institute, Atlanta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Emory University, Atlanta
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Nagre-recruitPhase 4
- Emory University, Atlanta
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Nagre-recruitPhase 1
- Research Site, Atlanta
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Emory University Hospital, Atlanta
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Nagre-recruitPhase 2/3
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Winship Cancer Institute of Emory University, Atlanta
Collection of Tissue Samples for Cancer Research
Nagre-recruitObservasyonal na pag-aaral
- Emory University, Atlanta
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Nagre-recruitPhase 3
- Winship Cancer Institute, Emory University, Atlanta
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Nagre-recruitPhase 3
- Emory University Hospital Midtown, Atlanta
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Nagre-recruitPhase 2
- Emory University/Winship Cancer Institute, Atlanta
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Emory University Hospital, Atlanta
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Research Site, Atlanta
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Nagre-recruitPhase 1/2
- Research Site, Atlanta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- The Winship Cancer Institute of Emory University, Atlanta
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Atlanta
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Atlanta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Nagre-recruitPhase 1
- Winship Cancer Institute, Emory University, Atlanta
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Winship Cancer Institute, Emory University, Atlanta
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Nagre-recruitPhase 4
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Nagre-recruitPhase 1/2
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Northside Hospital, Atlanta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Nagre-recruitPhase 1
- Winship Cancer Institute of Emory University, Atlanta
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Nagre-recruitPhase 1/2
- Emory Winship Cancer Institute, Atlanta
Personalized Autologous Transplant for Multiple Myeloma
Nagre-recruitPhase 1
- Winship Cancer Institute of Emory University, Atlanta
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Nagre-recruit
- Emory University Hospital/Winship Cancer Institute, Atlanta
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Nagre-recruitPhase 3
- Emory University Hospital, Atlanta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Emory Winchip Cancer Center, Atlanta
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Nagre-recruitPhase 3
- GSK Investigational Site, Atlanta
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Emory University Hospital, Atlanta
CAR T-cell Therapy in Patients With Renal Dysfunction
Nagre-recruitPhase 2
- Caitlin Guzowski, Atlanta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Nagre-recruitPhase 1
- Winship Cancer Institute, Atlanta
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Nagre-recruitPhase 1/2
- Emory University Hospital, Atlanta
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Nagre-recruitPhase 1
- Northside Hospital, Atlanta
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO26 pag-aaral
- Columbus, OH24 pag-aaral
- Rochester, MN24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- St. Louis, MO23 pag-aaral
- Chicago, IL22 pag-aaral
- Washington, DC22 pag-aaral
Iba pang pag-aaral sa Atlanta
- Kanser (lahat ng uri)50 pag-aaral
- Non-Small Cell Lung Cancer46 pag-aaral
- Kanser sa Suso41 pag-aaral
- Kanser sa Prostate32 pag-aaral
- Kanser sa Baga29 pag-aaral
- Colorectal Cancer29 pag-aaral
- Acute Myeloid Leukemia29 pag-aaral
- Kanser sa Ovary28 pag-aaral
- Metastatic Cancer27 pag-aaral
- Obesity25 pag-aaral
- Pagkabigo ng Puso25 pag-aaral
- Major Depressive Disorder24 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.